Sign up USA
Proactive Investors - Run By Investors For Investors

Soleno Therapeutics shares surge on positive patent news

The firm has received a new patent (9,757,384) from the relevant US office, it said in a statement
Soleno Therapeutics shares surge on positive patent news
The firm is developing a Diazoxide Choline Controlled Release Tablet (DCCR), it said

Soleno Therapeutics Inc (NASDAQ:SLNOW) shares added almost 50% in New York as the biopharma group issued positive patent news.

The firm has received a new patent (9,757,384) from the relevant US office, related to the use of certain pharmaceutical formulations to reduce one or more aggressive behaviours in a patient with genetics disorders Prader-Willi syndrome (PWS) or Smith-Magenis syndrome (SMS).

The firm is developing a Diazoxide Choline Controlled Release Tablet (DCCR).

“This patent will further strengthen the intellectual property portfolio for DCCR, our lead product candidate, for the treatment of PWS,” said Anish Bhatnagar, Soleno Therapeutics' chief executive in a statement today.

"Importantly, this most recent patent will provide protection of associated claims into 2035. We expect to leverage additional intellectual property opportunities for DCCR over the coming months.”

Soleno expects to begin a Phase III clinical trial of DCCR in Prader-Willi syndrome (PWS) by the end of 2017.

It is now finalising the design of a randomized, double-blind placebo-controlled study to treat around 100 patients.

This study is expected to take around nine to 12 months to complete. DCCR has orphan drug status for the treatment of PWS in the USA.

View full SLNOW profile View Profile

Related Articles

eye-766166_1280_583251a48f148.jpg
November 20 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.
Cancer cells
September 05 2017
In an initiation note on the company, finnCap’s analysts noted that ANGLE is focused on the development of Parsortix, an instrument platform with recurring revenues designed to isolate and harvest rare circulating tumour cells from a patient’s blood sample
clinical-trial.jpg
June 30 2017
In all 200 suffers were recruited to the trial and all of them have now past the three month stage.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use